------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (Date of earliest event reported): April 30, 1998
---------------
TWINLAB CORPORATION
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-21003 11-3317986
- --------------------------------------------------------------------------------
(State or other jurisdiction of (Commission file number) (I.R.S. employer
incorporation or organization) identification no.)
150 Motor Parkway, Hauppauge, New York 11778
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (516) 467-3140
-------------------
2120 Smithtown Avenue, Ronkonkoma, New York 11779
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
------------------------------------------------------
<PAGE>
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
On April 30, 1998, Twinlab Corporation ("Twinlab" or the "Company")
completed the acquisition of substantially all of the assets and assumed certain
liabilities of the Bronson division ("Bronson") of Jones Medical Industries,
Inc. ("Jones") (the "Acquisition"). The purchase price for the Acquisition was
$55.0 million in cash, subject to certain post-closing adjustments. The purchase
price was funded with a portion of the net proceeds from the sale by the Company
of 4,228,749 shares common stock in a public offering consummated in April,
1998.
Bronson manufactures, markets and distributes a line of over 350
vitamins, herbs, nutritional supplements and health and beauty aids, which are
sold under the Bronson(R) name through catalogs and direct mailings to
customers, including healthcare and nutritional professionals and mail order and
retail customers. Bronson also markets its MD Pharmaceutical(R) brand
exclusively to United States military commissaries.
Bronson's products, as well as private label nutritional supplements of
other companies, are manufactured in a 30,000 square foot facility in Tempe,
Arizona, which is included in the assets the Company acquired from Jones. The
Company presently intends to use the plant to manufacture Bronson's products and
to manufacture nutritional supplements of other companies on a contract
manufacturing basis.
Pursuant to a Transition Services Agreement entered into by Jones, Twin
Laboratories Inc. ("Twin Laboratories"), a wholly owned subsidiary of the
Company, and Bronson Laboratories, Inc. ("BLI"), a wholly owned subsidiary of
Twin Laboratories, Jones will continue to provide sales services and packaging
and distribution operations for Bronson through December 31, 1998.
2
<PAGE>
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED.
It is presently impracticable to provide the financial statements
required to be included in the Current Report on Form 8-K with respect to the
business acquired. Such financial statements will be filed under cover of Form
8-K/A as soon as practicable.
(b) PRO FORMA FINANCIAL INFORMATION.
It is presently impracticable to provide the pro forma financial
information required to be included in this Current Report on Form 8-K with
respect to the business required. Such pro forma financial information will be
filed under cover of Form 8-K/A as soon as practicable.
(c) EXHIBITS.
Asset Purchase Agreement, dated as of March 17, 1998 by and among
Jones, JMI-Phoenix Laboratories, Inc. BLI and Twin Laboratories.
3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
May 12, 1998 TWINLAB CORPORATION
By: /s/ Brian Blechman
------------------
Brian Blechman
Executive Vice President
4
ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT ("Agreement") is made and entered into as
of the 17th day of March, 1998, by and among JONES MEDICAL INDUSTRIES, INC., a
Delaware corporation ("JMED"), JMI-PHOENIX LABORATORIES, INC., an Arizona
corporation ("JMI-Phoenix"), TWIN LABORATORIES INC., a Utah corporation ("Twin
Labs"), and BRONSON LABORATORIES, INC., a Delaware corporation ("BLI"). JMED and
JMI-Phoenix are sometimes referred to herein individually as "Seller" and
collectively as "Sellers", and Twin Labs and BLI are sometimes referred to
herein individually as "Buyer" and collectively as "Buyers."
RECITALS:
A. JMED markets and distributes the branded vitamin and nutritional
supplement products set forth on Schedule A of the Disclosure Schedule ("Branded
Vitamin Products") under the Bronson Pharmaceutical and MD Pharmaceutical
tradenames.
B. JMI-Phoenix, a wholly-owned subsidiary of JMED, manufactures for JMED
those Branded Vitamin Products set forth on Schedule B of the Disclosure
Schedule, and performs contract manufacturing of vitamin and nutritional
supplement products and herbal teas for others ("Contract Manufactured
Products") in two adjacent buildings consisting of approximately 30,000 square
feet and located in Tempe, Arizona (the "JMI-Phoenix Facility"). The
manufacturers set forth on Schedule C of the Disclosure Schedule manufacture for
JMED those Branded Vitamin Products set forth on Schedule C of the Disclosure
Schedule.
C. Sellers desire to sell, and BLI, a wholly-owned subsidiary of Twin Labs,
desires to purchase, (i) the entire line of Branded Vitamin Products and herbal
teas; (ii) substantially all of the assets utilized by JMI-Phoenix and JMED in
blending, tableting, encapsulating, manufacturing,
1
<PAGE>
selling, packaging, marketing or distributing (collectively, "Manufacturing")
the Branded Vitamin Products and the Contract Manufactured Products; and (iii)
the JMI-Phoenix Facility, all pursuant to the provisions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing recitals and the
covenants contained herein, the parties agree as follows:
1. SALE OF ASSETS
1.01 Transfer of Assets. Subject to and upon the terms and conditions
of this Agreement, Sellers shall sell, convey, transfer, assign and deliver to
BLI, and BLI shall purchase (and Twin Labs shall cause BLI to purchase) from
Sellers, on the Closing Date (as hereinafter defined), all of Sellers' right,
title and interest in and to the following described assets (collectively, the
"Acquired Assets"):
(a) All trade accounts receivable and credit card receivables in
existence on the Closing Date with respect to sales of Branded Vitamin Products
and sales and manufacture of Contract Manufactured Products to all parties other
than JMED and its Affiliates set forth on Schedule 1.01(a) of the Disclosure
Schedule (collectively, the "Receivables");
(b) All raw material (including packaging materials), work in process
and finished goods inventory in existence on the Closing Date wherever located
with respect to the Business (collectively, the "Inventory");
(c) All machinery, equipment, tooling, supplies and related assets: (i)
of JMED which are specifically set forth on Schedule 1.01(c)(i) of the
Disclosure Schedule; and (ii) located at the JMI-Phoenix Facility or the Leased
Property, including those assets which are specifically set
2
<PAGE>
forth on Schedule 1.01(c)(ii) of the Disclosure Schedule (the assets described
in items (i) and (ii) are hereinafter collectively referred to as the "Fixed
Assets");
(d) All contract rights (including those Receivables identified in
Section 1.01(a) above), open sale orders from third parties and invoices to
third parties, license agreements, distributor agreements, royalty agreements
and other agreements of Sellers, if any, to the extent relating to the Business,
including those set forth on Schedule 1.01(d) of the Disclosure Schedule (the
"Contract Rights");
(e) (i) The registered United States trademarks, trade names and
service marks set forth on Schedule 1.01(e)(i) attached hereto, the
registrations thereof and all goodwill and all rights of Sellers of every kind,
nature and description connected therewith, and (ii) all United States and
foreign unregistered trademarks, trade names, service marks, patents and
copyrights, other than those set forth on Schedule 1.01(e)(ii) of the Disclosure
Schedule, to the extent relating to the Business (the "Intellectual Property");
(f) Except as set forth on Schedule 1.01(f) of the Disclosure Schedule,
all know-how, trade secrets, technology, methods of operation, procedures,
systems, computer programs, computer data, software, processes, production
details, inventions, recipes, formulas, designs, literature, artwork, brochures,
sales material, toll-free telephone numbers, specifications, advertising and
promotional materials and other proprietary rights of Sellers of every kind,
nature and description, to the extent relating to the Business;
(g) All customer and supplier lists, files, records, data bases, claim
substantiation materials, software and other similar information to the extent
relating to the Business;
3
<PAGE>
(h) All real property, leaseholds, improvements, fixtures, easements,
rights of way and other appurtenants relating to the JMI-Phoenix Facility as set
forth on Schedule 1.01(h) of the Disclosure Schedule (the "Real Property").
1.02 Excluded Assets. Notwithstanding anything contained herein to the
contrary, Sellers are not selling, conveying, assigning or transferring to
Buyers, and Buyers are not purchasing from Sellers, (i) any right, title or
interest in or to the products Panthoderm, Therevac and the Derma Soap line (the
"Excluded Products") and all files, records, data, customer lists and other
materials to the extent pertaining to the Excluded Products, (ii) any and all
retained lab samples of Products Manufactured by Sellers prior to the Closing
Date (the "Retention Samples"), and (iii) any and all manufacturing and batch
records pertaining to Products Manufactured by Sellers prior to the Closing Date
(collectively, "Batch Records"), and (iv) any other assets of Sellers not
identified or referred to in Section 1.01 hereof.
1.03 Assumption of Liabilities and Obligations. As of the Closing Date,
and subject to the provisions of this Agreement, Buyers expressly agree to
assume and discharge, or perform, in a timely manner, the contracts, obligations
and liabilities of Sellers specifically identified on Schedule 1.03 of the
Disclosure Schedule (the "Assumed Liabilities"). Buyers expressly do not, and
shall not, assume or be deemed to assume, under this Agreement or otherwise by
reason of the transactions contemplated by this Agreement or otherwise, any
liabilities or obligations of Sellers: (i) other than the Assumed Liabilities;
or (ii) that relate in any way to plantain used in Products Manufactured by
either Seller prior to the Closing Date.
4
<PAGE>
2. PURCHASE PRICE
2.01 Purchase Price.
(a) Within sixty (60) calendar days following the Closing Date, Sellers
shall deliver to Buyers an unaudited balance sheet relating solely to the
Business dated as of the Closing Date ("Closing Balance Sheet-Nutritionals").
The Closing Balance Sheet-Nutritionals shall be prepared in accordance with
generally accepted accounting principles applied consistent with the accounting
principles utilized in the preparation of the Audited Financial
Statements-Nutritionals (as defined in Section 5.09), for the purpose of
determining Net Working Capital (as defined below). For purposes of this Article
2, "Net Working Capital" shall mean the amount by which the "Current Assets" of
the Business (as classified on the Closing Balance Sheet-Nutritionals) exceed
the "Current Liabilities" of the Business (as classified on the Closing Balance
Sheet-Nutritionals). For purposes hereof, "Current Assets" shall mean Total
Assets (as classified on the Closing Balance Sheet - Nutritionals) less the sum
of (i) cash, (ii) intangibles, and (iii) net property, plant and equipment, and
"Current Liabilities" shall mean the sum of (x) accounts payable, (y) unused
credits, and (z) accrued vacation/salaries.
(b) The purchase price ("Purchase Price") to be paid by Buyers to
Sellers for the Acquired Assets is Fifty-Five Million and No/100 Dollars
($55,000,000.00), subject to adjustments as provided in Section 2.02 below.
2.02 Purchase Price Adjustments. (a) The Purchase Price shall be reduced in
the event that the Net Working Capital as determined by reference to the Closing
Balance Sheet-Nutritionals is less than Eight Million Five Hundred Thousand
dollars ($8,500,000) and the amount of any such aggregate adjustment shall be a
dollar for dollar reduction equal to the dollar amount of any such deficiency
("Purchase Price Adjustment - Net Working Capital"). For example, if the Net
Working Capital shown on the Closing Balance Sheet-Nutritionals is $8,400,000,
then the
5
<PAGE>
Purchase Price shall be reduced by $100,000 and said $100,000 shall be paid by
Sellers to Buyers as hereinafter set forth.
(b) The Purchase Price shall be reduced in the event that Operating
Income Before Amortization as shown on the Audited Operating Statement (as
hereinafter defined in Section 5.09 hereof) (the "Audited OIBA") is less than
Ten Million Dollars ($10,000,000), and the amount of any such aggregate
adjustment shall be a reduction equal to five (5) times the dollar amount by
which Audited OIBA is less than Ten Million One Hundred Thousand Dollars
($10,100,000). For example, (i) if Audited OIBA is $10,050,000, then the
Purchase Price will not be adjusted, and (ii) if Audited OIBA is $9,900,000,
than the Purchase Price shall be reduced by $1,000,000 (5 x $200,000) and either
(A) if Closing has not yet occurred, then the Purchase Price shall be reduced at
Closing, and (B) if Closing has occurred, then the amount of the reduction shall
be paid by Sellers to Buyers within ten (10) days after Sellers receipt of the
Audited Operating Statement.
(c) Subject to the provisions of Section 2.06 hereof, the Purchase
Price Adjustment-Net Working Capital shall be paid by the Sellers to the Buyers
within five (5) days after expiration of the Dispute Period (as defined in
Section 2.06 below).
2.03 Payment of Purchase Price. The Purchase Price shall be paid by
Buyers to Sellers at Closing by wire transfer of immediately available funds to
an account designated in writing by JMED (the "Closing Payment").
2.04 Transfer Taxes. Buyers shall be liable for and shall pay all state
and local sales and use taxes, if any, payable in connection with the conveyance
and transfer of the Acquired Assets by Sellers to Buyers.
6
<PAGE>
2.05 Allocation. The Purchase Price shall be allocated among the
Acquired Assets, as set forth on Schedule 2.05 of the Disclosure Schedule
attached hereto.
2.06 Disputes Regarding Net Working Capital.
(a) Buyers shall have thirty (30) days after receipt of the Closing
Balance Sheet-Nutritionals ("Dispute Period") to dispute any of the elements of
or amounts reflected in the Closing Balance Sheet-Nutritionals (a "Dispute"). If
the Buyers have a Dispute, Buyers shall deliver to the Sellers written notice
("Dispute Notice") within the Dispute Period, setting forth a description of the
Dispute. Within ten (10) days after the receipt by Sellers of any Dispute
Notice, Sellers and Buyers shall meet at a mutually acceptable time and place
and shall, in good faith, cooperate in an attempt to resolve such Dispute. If
Buyers do not give Sellers a Dispute Notice within the Dispute Period, then
there shall be no adjustment to the Purchase Price.
(b) If any Dispute is not finally resolved within twenty (20) days
after the receipt by Sellers of a Dispute Notice, then the Dispute shall be
referred to the St. Louis office of Price Waterhouse, LLP (or its successor)
(the "Arbitrator") for resolution in accordance with the terms hereof (the
"Arbitration"), and in any event as soon as practicable.
(c) The Arbitrator shall hold a hearing within thirty (30) days of the
submission of the Dispute for Arbitration (the "Hearing") and shall render a
written decision to each party hereto within thirty (30) days of the conclusion
of the Hearing ("Arbitrator's Decision"). The Arbitrator shall have the same
access as the Buyers to any documentation used in the calculation of the Net
Working Capital. Any decision made by the Arbitrator within the scope of its
authority shall be final, binding and non-appealable.
(d) The fees and expenses of the Arbitrator shall be borne (A) by the
Buyers in the event that Sellers' calculation of Net Working Capital as shown on
the Closing
7
<PAGE>
Balance Sheet-Nutritionals was closer in dollar amounts to the Arbitrator's
determination than was Buyers' calculation thereof, and (B) by Sellers in the
event that Buyers' calculation of Net Working Capital was closer in dollar
amounts to the Arbitrator's determination than was Sellers' calculation thereof.
Notwithstanding the foregoing, each of the parties shall bear their own costs
and expenses related to any such Arbitration.
(e) If the Arbitrator determines that a Purchase Price Adjustment is
required, then such Purchase Price Adjustment as determined by the Arbitrator
shall be paid by the Sellers to the Buyers within five (5) days after Sellers'
receipt of the Arbitrator's Decision.
3. TRANSITION SERVICES AGREEMENT. At the Closing (as hereinafter defined)
of the transactions contemplated by this Agreement, JMED and Buyers shall enter
into a Transition Services Agreement in the form of Exhibit A attached hereto.
4. CLOSING.
4.01 Date, Place and Time. The closing of the transactions contemplated
by this Agreement (the "Closing") shall take place at the offices of
Greensfelder, Hemker & Gale, P.C., 10 South Broadway, Suite 2000, St. Louis,
Missouri 63102, commencing at 10:00 a.m. (local time) on the third business day
following the satisfaction or waiver of all conditions to the obligations of the
parties to consummate the transactions contemplated hereby or at such other
place or time as the parties shall mutually determine (the "Closing Date").
4.02 Sellers' Deliveries at Closing. At Closing, Sellers shall deliver
or cause to be delivered to Buyers in accordance with this Agreement:
(a) a Bill of Sale in the form of Exhibit B attached hereto, duly
executed;
(b) an Assignment of Trademarks in the form of Exhibit C attached
hereto, duly executed;
8
<PAGE>
(c) the Transition Services Agreement, duly executed;
(d) a Special Warranty Deed in the form of Exhibit D attached hereto,
duly executed;
(e) all such certificates, affidavits, consents, assignments and other
documents deemed reasonably necessary by Buyers to effectively sell, assign and
transfer the Acquired Assets to Buyers and to comply with the provisions of this
Agreement; and
(f) the Noncompete Agreement in the form of Exhibit H attached hereto,
duly executed.
4.03 Buyers' Deliveries at Closing. At the Closing, Buyers shall
deliver or cause to be delivered to Sellers in accordance with this Agreement:
(a) the Closing Payment;
(b) an Assignment and Assumption Agreement in the form of Exhibit E
attached hereto, duly executed;
(c) the Transition Services Agreement, duly executed;
(d) all such certificates, affidavits, consents, assignments and other
documents deemed reasonably necessary by Sellers to effectively sell, assign and
transfer the Acquired Assets to Buyers and to comply with the provisions of this
Agreement; and
(e) the Noncompete Agreement, duly executed.
5. REPRESENTATIONS AND WARRANTIES OF SELLERS. Sellers represent and warrant
to Buyers that the statements contained in this Section 5 are true and correct
in all material respects as of the date of this Agreement and will be true and
correct in all material respects as of the Closing Date (as though made then and
as though the Closing Date were substituted for the date of this Agreement
throughout this Section 5), except as specifically set forth in the
corresponding
9
<PAGE>
section of the disclosure schedule accompanying this Agreement (the "Disclosure
Schedule"). The Disclosure Schedule will be arranged in paragraphs corresponding
to the numbered and lettered Sections and paragraphs of this Agreement.
5.01 Organization and Good Standing. Each of JMED and JMI-Phoenix is a
corporation duly incorporated, validly existing and in good standing under the
laws of the States of Delaware and Arizona, respectively, and each has all
requisite corporate power and lawful authority to carry out all of the
provisions of this Agreement and the transactions contemplated hereby on its
part to be performed.
5.02 Authorization of Transaction. Each Seller has full corporate power
and authority to execute and deliver this Agreement and all other documents
executed incident hereto or in connection herewith (collectively the
"Transaction Documents") and to perform its respective obligations hereunder and
thereunder. Without limiting the generality of the foregoing, the board of
directors of each Seller has duly authorized the execution, delivery and
performance of the Transaction Documents. The Transaction Documents constitute
the valid and legally binding obligations of each Seller, enforceable against
each Seller in accordance with their respective terms and conditions.
5.03 Noncontravention. (a) Except as set forth in Schedule 5.03(a) of
the Disclosure Schedule, the execution and delivery by each of the Sellers of
this Agreement and the other Transaction Documents, and the transactions
contemplated hereby or thereby, and compliance by each of the Sellers with any
of the provisions hereof or thereof does not and will not (i) conflict with, or
result in the breach of, any provision of the Certificate of Incorporation or
Bylaws of either Seller; (ii) conflict with, violate, result in the breach or
termination of, or constitute a default or give rise to any right of termination
or acceleration or right to increase the obligations or otherwise
10
<PAGE>
modify the terms thereof under any Contract or Order to which either Seller is a
party or by which either Seller or the properties or assets of either Seller are
bound; (iii) constitutes a violation of any Law applicable to either Seller; or
(iv) result in the creation of any Lien upon the properties or assets of either
Seller in each case that relate to the Business or Acquired Assets. Except as
set forth on Schedule 5.03(a) of the Disclosure Schedule, no consent, waiver,
approval, registration, license, permit or authorization of , or declaration or
filing (other than for compliance with the HSR Act) with, or notification to,
any Person or Governmental Body is required on the part of either Seller in
connection with the execution and delivery of this Agreement or the other
Transaction Documents, or the compliance by either Seller with any of the
provisions hereof or thereof.
(b) Except as set forth on Schedule 5.03(b) of the Disclosure Schedule,
neither Seller is a party to any agreement, contract or covenant limiting the
freedom of either Seller to compete in any line of business or with any Person
in any geographic region within or outside the United States of America, in each
case that relates to the Business or Acquired Assets.
5.04 Title, Delivery of Assets. Sellers are the sole, true and lawful
owners of the Acquired Assets and have all necessary power and authority to sell
the Acquired Assets to Buyer, free and clear of all Liens, other than those set
forth on Schedule 5.04 of the Disclosure Schedule. Upon delivery to Buyer of the
Bill of Sale, the Special Warranty Deed and the Assignment of Trademarks, Buyer
will acquire good and valid title to the Acquired Assets, free and clear of all
Liens, other than those restrictions of record with respect to the Real
Property.
5.05 Compliance with Laws. (a) Except as set forth on Schedule 5.05(a)
of the Disclosure Schedule, each Seller is and at all times has been in
compliance in all material respects with all Laws and Orders promulgated by any
Governmental Body applicable to the Sellers (including all applicable Food and
Drug Administration ("FDA"), Federal Trade Commission
11
<PAGE>
("FTC"), Consumer Products Safety Commission ("CPSC") and the United States
Department of Agriculture ("USDA") rules and regulations), or to the conduct of
the business or operations of Sellers or the use of the properties (including
any leased properties) and assets of Sellers, in each case that relate to the
Business or the Acquired Assets. Except as set forth on Schedule 5.05(a) of the
Disclosure Schedule, neither Seller has received, and to the Knowledge of
Sellers there has been no issuance of, any notices or violation or alleged
violation by either Seller of any such Law or Order during the last three (3)
years, in each case relating to the Business or the Acquired Assets. Except as
set forth on Schedule 5.05(a), there is no investigation or review by any
Governmental Body with respect to either Seller pending, or to the Knowledge of
Sellers, threatened, nor has any Governmental Body notified either Seller of its
intention to conduct the same, in each case as the same may relate to the
Business or Acquired Assets.
(b) Schedule 5.05(b) of the Disclosure Schedule lists all Permits of
Sellers of all Governmental Bodies (including the FDA, the FTC, the CPSC, OSHA
and the USDA) which Permits constitute, to each Seller's Knowledge, all Permits
required by the nature of the operations of Sellers to permit the respective
operations in the manner in which they are currently conducted, in each case as
they relate to the Business or the Acquired Assets. Such Permits have been
validly issued to Sellers by the appropriate Governmental Bodies in compliance
with all applicable Laws, and Sellers have complied in all material respects
with all conditions of such Permits applicable to them. All such Permits are in
full force and effect. Sellers have not received any written, or to the
Knowledge of Sellers, oral notice of violation of any Permit except as set forth
on Schedule 5.05(b) of the Disclosure Schedule.
5.06 Actions and Proceedings. There are no Legal Proceedings pending or
to the Knowledge of either Seller threatened, that question the validity of this
Agreement or the other
12
<PAGE>
Transaction Documents or any action taken or to be taken in connection with the
consummation of the transactions contemplated hereby or thereby. Schedule 5.06
of the Disclosure Schedule sets forth a true, correct and complete list of all
Legal Proceedings pending or to the Knowledge of either Seller threatened,
against or affecting either Seller, or any properties or assets of either
Seller, at law or in equity in each case that relate to the Business or the
Acquired Assets. There is no outstanding, nor to Sellers' Knowledge, threatened,
Order of any Governmental Body against, affecting or naming either Seller or
affecting any of the business, properties or assets of either Seller, in each
case that relate to the Business or Acquired Assets.
5.07 Intellectual Property. Except as set forth on Schedule 5.07 of the
Disclosure Schedule or in Section 8.06 of this Agreement: (i) the Intellectual
Property is owned by Sellers free and clear of all Liens; (ii) the Intellectual
Property is not subject to any license, royalty arrangement, restriction or
dispute of any kind; (iii) to the Knowledge of Sellers, Sellers' use of the
Intellectual Property does not infringe, and is not infringing, on any
trademark, trade name, copyright, service mark or patent (or any application
therefor) of any Person, and Sellers have not received any claim or assertion to
such effect from any third party; and (iv) there exists no restriction on the
use or transfer of the Intellectual Property. To the Knowledge of Sellers, there
are no uses of the Intellectual Property by any third party that infringes upon
Sellers' rights in the Intellectual Property. 5.08 Brokers and Finders. Sellers
have not retained any broker or finder with respect to any of the transactions
contemplated by this Agreement.
5.09 Financial Information.
(a) Attached to Schedule 5.09 of the Disclosure Schedule are copies of:
(i) the unaudited Balance Sheet-Nutritionals as of December 31, 1997 ("Unaudited
Balance Sheet-Nutritionals"); and (ii) the related unaudited Operating
Results-Nutritionals for the year ended December 31, 1997 ("Unaudited Operating
Results-Nutritionals"). The Unaudited Balance Sheet-Nutritionals and Unaudited
Operating Results-Nutritionals are hereinafter referred to as the "Latest
Financials." The Latest Financials are true and complete in all material
respects and were prepared in good faith from the books and records of the
Sellers in accordance with generally accepted accounting principles consistently
applied (except with respect to normal and customary year-end adjustments and
the preparation of notes). The Sellers have arranged for the Latest Financials
to be audited by Ernst & Young LLP, and the resulting audited balance sheet is
herein referred to as the "Audited Balance Sheet" and the resulting audited
statement of operating results is herein referred to as the "Audited Operating
Statement".
(b) Since December 31, 1997, there has been no Material Adverse Change:
(i) with respect to the financial condition, assets or liabilities of the
Sellers as such relates to the Business except for a reduction in Net Working
Capital due to increased payables and a reduction in receivables and inventory
in the ordinary course of business consistent with past practice except for the
unusually high level of Net Working Capital at the end of 1997; and (ii) with
respect to the business of the Sellers as such relates to the Business.
5.10 No Undisclosed Liabilities. Sellers do not have any liabilities,
debts or claims against them with respect to the Business or the Acquired Assets
except: (i) to the extent indicated in the Latest Financials or the Audited
Balance Sheet; or (ii) those that have occurred or arisen in the ordinary course
of business consistent with past practice since December 31, 1997.
5.11 Contracts. Except as set forth on Schedule 5.11 of the Disclosure
Schedule, neither Seller nor any of their respective properties or assets which
pertain to the Business or Acquired Assets, is a party to or bound by any (i)
Contract not made in the ordinary course of
13
<PAGE>
business; (ii) advertising, public relations, franchise, distributorship or
sales agency Contract that cannot be terminated on thirty (30) days notice;
(iii) Contact involving a commitment or payment in excess of $50,000.00 in the
aggregate; (iv) Contract granting a right of first refusal for the acquisition,
sale or lease of any assets or a material portion of the capital stock of either
Seller; (v) Contract with any Person involving a sharing of profits; (vi)
mortgage, pledge, conditional sales contract, security agreement, factoring
agreement or other similar contract with respect to any real or tangible
personal property of either Seller; (vii) Contract with any Governmental Body;
(viii) Contract with respect to the discharge, storage or removal of Hazardous
Materials; or (ix) commitment or agreement to enter into any of the foregoing.
Sellers have delivered or otherwise made available to Buyer true, correct and
complete copies of the written Contracts listed in Schedule 5.11 of the
Disclosure Schedule, together with all amendments, modifications, supplements or
side letters affecting the obligations of any party thereunder.
(b) Each of the Contracts listed on Schedule 5.11 of the Disclosure
Schedule is valid and enforceable in accordance with its terms, and to each
Seller's Knowledge, there is no default under any such Contract by either Seller
or by any other party thereto, and to each Seller's Knowledge, no event has
occurred that with the lapse of time or the giving of notice or both would
constitute a default thereunder.
(c) No previous or current party to any Contract listed on Schedule
5.11 of the Disclosure Schedule has given notice to have or made a claim to
either Seller with respect to any breach or default thereunder.
5.12 Customers and Suppliers. Except as set forth in Schedule 5.12 of
the Disclosure Schedule, to each Seller's Knowledge, each Seller's relationship
with its respective customers and suppliers as the same pertains to the
Business, is a good commercial working
14
<PAGE>
relationship and neither Seller has any Knowledge that any such customer or
supplier intends to cancel or otherwise modify in a material way, its
relationship with the Business or to decrease materially or limit its usage or
purchase of any products manufactured in connection with the Business.
5.13 Inventory. The Inventory (other than obsolete or short dated items
which do not exceed $60,000) is of a type and quality usable and saleable in the
ordinary course of each Seller's respective business.
5.14 Receivables. The Receivables have arisen in the ordinary course of
business consistent with past practice, and represent valid obligations due each
respective Seller enforceable in accordance with their terms.
5.15 Fixed Assets. The Fixed Assets which are material to the operation
of the Business and the Acquired Assets are in working order and are suitable
for the purposes used for the operation by Sellers of the Business and the
Acquired Assets.
5.16 Labor Matters. Attached hereto as Schedule 5.16 of the Disclosure
Schedule is a listing of those employees of Sellers employed primarily in
connection with the JMI-Phoenix Facility, together with a listing of the wages,
salaries, bonuses or other compensation or benefit arrangements for each
respective employee as of the dates indicated (the "Transferred Employees").
There is no pending, or to either Seller's Knowledge, threatened controversy,
labor dispute, strike or work stoppage by any Transferred Employee(s). The
Transferred Employees are not represented by any union or collective bargaining
unit, and neither Seller is aware of any attempt to organize any of the
Transferred Employees into a collective bargaining unit.
5.17 Insurance. Schedule 5.17 of the Disclosure Schedule sets forth a
list of all policies of insurance of any kind or nature covering Sellers or any
of the respective employees,
15
<PAGE>
properties, assets or operations in each case that relate to the Business or
Acquired Assets, including without limitation, policies of life, disability,
fire, theft, workers compensation, employee fidelity, product liability and
other casualty and liability insurance. All such policies are in full force and
effect.
5.18 Real Property. Attached to Schedule 5.18 is a true and complete
copy of the Lease (the "Lease") dated August 20, 1997, between University-Smith
Partners, as Landlord, and JMED, as Tenant, for space at 227 South Smith Road,
#103, Tempe, Arizona (the "Leased Property"), and the same is in full force and
effect and has not been modified, amended or extended in any manner. Sellers are
not in default under any terms of the Lease and have made payment of all rent
and other charges due thereunder through the date hereof; and Sellers have not
sent any notice of default to the Landlord under the Lease and, to the Knowledge
of Sellers, the Landlord under the Lease is not in default. Except as set forth
on Schedule 5.18 of the Disclosure Schedule:
(a) There is no owned or leased real property utilized by either Seller
with respect to the manufacture, packaging or sale of Branded Vitamin Products
or Contract Manufactured Products;
(b) There are no pending or, to the Knowledge of Sellers, threatened
condemnation proceedings, lawsuits or administrative actions relating to the
Real Property or other matters affecting materially and adversely the current
use or occupancy thereof;
(c) There are no leases, subleases, licenses or other agreements,
written or oral, granting to any party or parties the right or use or occupy any
portion of the Real Property; (d) There no parties other than Sellers in
possession of the Real Property; and
16
<PAGE>
(e) All facilities located on each parcel of Real Property are supplied
with utilities and other services necessary for the operations of the facilities
as currently being operated in accordance with all applicable Laws.
5.19 Disclosures. None of this Agreement, any other Transaction
Document, or any Schedule or Exhibit attached hereto, or any Transaction
Document, contains any untrue statement of a material fact or omits any material
fact necessary in order to make the statements contained herein or therein not
misleading. There is no fact that has not been disclosed to Buyer in writing
that materially and adversely affects the Business or the ability of Sellers to
perform the transactions contemplated by this Agreement. The representations and
warranties contained in this Agreement or in any other Transaction Document
shall not be affected or deemed waived by reason of the fact that either Buyer
knew or should have known that any such representation or warranty is or might
be inaccurate in any respect.
5.20 Environmental Matters. Except as set forth on Schedule 5.20 of the
Disclosure Schedule: (i) to the Knowledge of Sellers, the operations of Sellers
relating to the Business or the Acquired Assets have been and presently are in
compliance with all Environmental Laws; (ii) neither Seller has received any
written notice from any source, or has otherwise obtained Knowledge, to the
effect that there is lacking any Environmental Permit required in connection
with the current use or operation of any of their respective facilities relating
to the Business or the Acquired Assets; (iii) Sellers and their respective
facilities and operations relating to the Business or the Acquired Assets are
not subject to any outstanding written Order or Contract with any Governmental
Body or Person, or subject to any federal, state or local investigation
respecting (A) Environmental Laws, (B) any Remedial Action, or (C) any
Environmental Claim arising from the Release or threatened Release of a
Hazardous Material by either Seller; (iv) neither Seller has caused
17
<PAGE>
or permitted with respect to the Business or the Acquired Assets, any Hazardous
Material to remain or be disposed of, except in accordance with all applicable
Laws; (v) the Sellers are not aware of any facts, conditions or circumstances
which could reasonably be expected to form the basis of an Environmental Claim
against Sellers or Buyers except as set forth on Schedule 5.20 of the Disclosure
Schedule; and (vi) the operations of Sellers relating to the Business or the
Acquired Assets do not involve the generation, transportation, treatment,
storage or disposal of Hazardous Waste as defined under 40 C.F.R. Parts 260 -
270 (in effect as of the date of this Agreement), except in accordance with all
applicable Laws. To the Knowledge of Sellers and except as disclosed at
disclosure 7 on Schedule 5.05(a), there are no material capital expenditures
that would be required to bring the JMI-Phoenix Facility into compliance with
applicable Environmental Laws or Environmental Permits. To Sellers' Knowledge
and except as disclosed on the Phase I study ordered by Buyers, with respect to
the JMI-Phoenix Facility, there is not now on the property any underground
storage tank or surface tank, any asbestos containing material, or any
polychlorinated biphenyls in violation of applicable Laws.
5.21 Entire Business. Except as set forth on Schedule 5.21 of the
Disclosure Schedule, the Acquired Assets constitute all of the material tangible
and intangible assets necessary for Buyers to conduct the Business in
substantially the same manner as conducted by Sellers prior to Closing. The
Branded Vitamin Products constitute all branded vitamin, herb and nutritional
supplement products Manufactured by either Seller under the Bronson
Pharmaceutical or MD Pharmaceutical tradenames.
5.22 Product Liability and Recalls. (a) Except as disclosed on Schedule
5.22(a) of the Disclosure Schedule, neither Seller is aware of any claims which
are in excess of $25,000 individually, or $100,000 in the aggregate, or the
basis of any material claims which are reasonably
18
<PAGE>
likely to be in excess of $25,000 individually or $100,000 in the aggregate,
against either Seller for injury to person or property of employees or any third
parties suffered as a result of the Manufacture of any Products or the
performance of any service by either Seller, including claims arising out of the
allegedly defective or unsafe nature of the Products sold or distributed by
either Seller, in each case that relate to the Business or the Acquired Assets.
(b) Except as disclosed on Schedule 5.22(b) of the Disclosure Schedule,
there is no pending or, to the Knowledge of either Seller, threatened recall or
investigation of any Product.
(c) There are no material liabilities or to each Seller's Knowledge,
threatened claims for returns or warranty obligations with respect to any
Product.
5.23 Conduct of Business. Except as set forth on Schedule 5.23 of the
Disclosure Schedule, since December 31, 1997, Sellers, with respect to the
Business or the Acquired Assets, have not done, nor have either of them agreed
to do, any of the following:
(a) enter into any material transaction not in the ordinary course of
business;
(b) dispose of any of their assets, except in the ordinary course of
business consistent with past practice;
(c) enter into any material lease or contract for the purchase or sale
or license of any property, real or personal, except in the ordinary course of
business consistent with past practice;
(d) fail to maintain their equipment and other assets in working
condition according to the standards they have maintained to the date of this
Agreement, subject only to ordinary wear and tear;
19
<PAGE>
(e) amend or terminate any contract, agreement or license to which they
are a party, except those amended or terminated in the ordinary course of
business, consistent with past practice, and which are not material in amount or
effect;
(f) waive or release any right or claim except for the waiver or
release of non-material claims in the ordinary course of business, consistent
with past practice;
(g) extend or otherwise modify the payment terms for Inventory, except
in the ordinary course of business, consistent with past practice; or
(h) make any material changes in their accounting methods or practice;
or
(i) materially change any of their business practices. 5.24 Year 2000
Compliance. Attached hereto as Schedule 5.24 of the Disclosure Schedule is a
memo received by Sellers with respect to year 2000 compliance. No representation
or warranty is made by Sellers with respect to year 2000 compliance.
6. REPRESENTATIONS AND WARRANTIES OF BUYER. Buyers represent and warrant to
Sellers that the statements contained in this Section 6 are true and correct in
all material respects as of the date of this Agreement and will be true and
correct in all material respects as of the Closing Date (as though made then and
as though the Closing Date were substituted for the date of this Agreement
throughout this Section 6).
6.01 Organization; Corporate Power. Twin Labs is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Utah, and has all requisite corporate power and lawful authority to carry out
all of the provisions of this Agreement on its part to be performed. BLI is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware, and has all requisite corporate power and lawful
authority to carry
20
<PAGE>
out all of the provisions of this Agreement on its part to be performed. BLI is
a wholly-owned subsidiary of Twin Labs.
6.02 Authorization of Transaction. Each Buyer has full corporate power
and authority to execute and deliver the Transaction Documents and to perform
their respective obligations hereunder and thereunder. Without limiting the
generality of the foregoing, the board of directors of each Buyer has duly
authorized the execution, delivery and performance of the Transaction Documents
by each Buyer. The Transaction Documents constitute the valid and legally
binding obligations of each Buyer, enforceable against each Buyer in accordance
with their respective terms and conditions.
6.03 Noncontravention. Neither the execution of the Transaction
Documents, nor the performance of the transactions contemplated thereby, by
either Buyer: (i) violates any provision of any Law; or (ii) requires any
approval, consent, waiver, registration, license, permit, authorization, or
withholding of objections on the part of any Person (except for compliance with
the HSR Act); or (iii) conflicts with, results in a breach of or constitutes a
default under any indenture, mortgage, agreement, note, lease or other
instrument or document of which each Buyer is a party; or (iv) violates the
Certificate of Incorporation or By-Laws of either Buyer.
6.04 Brokers and Finders. Neither Buyer has retained any broker or
finder except for W. E. Meyers & Company with respect to the transactions
contemplated by this Agreement. Each Buyer shall be jointly and severally
responsible for, and shall indemnify Sellers with respect to any and all fees,
commissions, remuneration or other monies owing to W. E. Meyers & Company with
respect to the transactions contemplated by this Agreement.
7. PRE-CLOSING COVENANTS. Sellers and Buyers agree as follows with respect
to the period between the execution of this Agreement and the Closing Date.
21
<PAGE>
7.01 General. Each of the parties will use its reasonable best efforts
to take all commercially reasonable action and to do all commercially reasonable
things necessary, proper or advisable in order to consummate and make effective
the transactions contemplated by this Agreement (including satisfaction, but not
waiver, of the Closing conditions set forth in Article 9 below).
7.02 Notice and Consents. Each of the parties will give any notices to,
make any filings with and use its reasonable best efforts to obtain any
authorizations, consents and approvals of any Governmental Body in connection
with the matters referred to in Sections 5.03 and 6.03 above. Without limiting
the generality of the foregoing, each of the parties will: (i) file any
notification and report forms and related material that may be required to be
filed with the Federal Trade Commission and the Antitrust Division of the United
States Department of Justice under the Hart-Scott-Rodino Act (the "HSR Act") so
that the filing is deemed received, and the applicable waiting period will begin
to run as of, March 19, 1998; (ii) use its reasonable best efforts to obtain an
early termination of the applicable waiting period thereunder; and (iii) make
any further filings pursuant thereto that may be necessary, proper or advisable
in connection therewith. The parties will coordinate and cooperate with one
another in exchanging information and providing reasonable assistance as the
other may request in connection with the foregoing. Except to the extent
required by any Law, Sellers will not introduce any new Products or materially
modify any existing Products Manufactured in the Business without consulting
with Buyers on a reasonable basis prior to taking any such action.
7.03 Operation and Preservation of Business. Sellers will not engage in
any practice, take any action, or enter into any transaction outside the
ordinary course of business in connection with the Business. Sellers will keep
their respective business and properties related to
22
<PAGE>
the Business substantially intact, including the present operations, physical
facilities, working conditions and relationships with suppliers, customers and
employees related thereto.
7.04 Access. Sellers will permit representatives of Buyers to have
access, after giving reasonable notice, at all reasonable times and in a manner
so as to not interfere with the normal business operations of each Seller, to
the premises, properties, books, records, contracts and documents of Sellers
pertaining to the Business, provided that Buyers shall not have the right to
copy or make records of any such items.
7.05 Notice of Developments. Each party will give prompt written notice
to the other party of any material adverse development causing a breach of any
of its own representations and warranties contained in this Agreement. No
disclosure by any party pursuant to this Section 7.05, however, shall be deemed
to amend or supplement the Disclosure Schedule or to prevent or cure any
misrepresentation, breach of warranty or breach of covenant.
7.06 Confidentiality. From and after the date of this Agreement until
the Closing Date, Buyers shall use the same efforts to maintain the
confidentiality of any proprietary or confidential information regarding the
Business as Buyers use to maintain the confidentiality of their own proprietary
information. In the event that there is no Closing Date under this Agreement,
Buyers shall return all information regarding the Business to Sellers, retaining
no copies, excerpts or other analysis or redactions of such information, and
Buyers covenant and agree that no such information shall be disclosed to any
third party or utilized in any way by Buyers in the conduct of their own
businesses.
7.07 Advice of Changes. During the period from the date of this
Agreement until the earlier of the Closing and the termination of this Agreement
in accordance with its terms, Sellers will promptly advise Buyers in writing,
and Buyers will promptly advise Sellers in writing (a) of
23
<PAGE>
any event occurring subsequent to the date of this Agreement that would render
any representation or warranty of such party contained in this Agreement, if
made on or as of the date of such event or the Closing Date, untrue or
inaccurate, (b) of any Material Adverse Change, and (c) of any breach by such
party of any covenant or agreement contained in this Agreement or any other
Transaction Document.
7.08 Maintenance of Business. From the date hereof until the earlier of
the Closing Date and the termination of this Agreement in accordance with its
terms, each Seller shall:
(a) cause to be done all things necessary to maintain, preserve and
renew (i) all material licenses, authorizations and permits necessary to the
conduct of the Business and (ii) its relationships with clients, customers,
suppliers, employees and others in substantially the same manner as it has prior
to the date hereof;
(b) comply in all material respects with all applicable Laws,
including, but not limited to, Environmental Laws, in each case that relate to
the Business or the Acquired Assets;
(c) maintain proper books of record and account which present fairly in
all material respects its financial condition and results of operations and make
provisions on its financial statements for all such proper reserves as in each
case are required in accordance with generally accepted accounting principles,
consistently applied, in each case that relate to the Business or the Acquired
Assets; and
(d) insofar as it may relate to the Business or the Acquired Assets,
not enter into any material transaction not in the ordinary course of its
business;
(e) not dispose of any of its assets related to the Business or the
Acquired Assets, except in the ordinary course of business consistent with past
practice;
24
<PAGE>
(f) not enter into any material lease or contract for the purchase or
sale or license of any property, real or personal, in connection with the
Business or the Acquired Assets, except in the ordinary course of business
consistent with past practice;
(g) maintain the equipment and other assets that are Acquired Assets in
working condition according to the standards it has maintained to the date of
this Agreement, subject only to ordinary wear and tear;
(h) not amend or terminate any contract, agreement or license to which
it is a party that relates to the Business or the Acquired Assets, except those
amended or terminated in the ordinary course of business, consistent with past
practice, and which are not material in amount or effect;
(i) not waive or release any right or claim in connection with the
Business or the Acquired Assets, except for the waiver or release of
non-material claims in the ordinary course of business, consistent with past
practice;
(j) not extend the payment terms for Inventory, except in the ordinary
course of business, consistent with past practice;
(k) not make any material change in its accounting methods or practices
with respect to the Business; or
(l) not materially change any business practices with respect to the
Business.
7.09 Securing Permits. Buyers shall use commercially reasonable efforts
to secure and obtain, as soon as reasonably practicable after the signing of
this Agreement, all Permits (other than those that require an OTC or
prescription drug license or registration) required to operate the Business and
Manufacture the Products in substantially the same manner as is currently being
25
<PAGE>
operated by Sellers, so as to satisfy the condition to close set forth in
Section 9.01(i) of this Agreement. From and after the signing of this Agreement,
Buyers shall keep Sellers informed with respect to Buyers' progress in obtaining
such Permits.
7.10 Securing Title Insurance. As soon as reasonably practicable after
the signing of this Agreement, Buyers shall use commercially reasonable efforts
to secure and obtain, at customary rates, a title insurance commitment (to be
followed by a title insurance policy at Closing) from a reputable title
insurance company licensed to do business in the State of Arizona, committing to
insure (and ultimately insuring at Closing) the fee interest title in the Real
Property to be acquired hereunder by BLI, free and clear of all Liens other than
those disclosed on Schedule 5.04 of the Disclosure Schedule (provided that the
same will not interfere with the use of the Real Property or the structures
thereon to the extent currently used by Sellers), so as to satisfy the condition
to close set forth in Section 9.01(k) of this Agreement. From and after the
signing of this Agreement, Buyers shall keep Sellers informed with respect to
Buyers' progress in obtaining such title insurance.
8. COVENANTS AND AGREEMENTS.
8.01 Employee Matters. Buyers covenant and agree to offer employment on
the Closing Date on an "at will" basis to all Transferred Employees. As of the
Closing Date, all Transferred Employees will be eligible to participate in all
benefit programs maintained by Buyers, including without limitation, benefit
programs relating to medical insurance, dental insurance, life insurance and
disability (collectively, "Health Plans") and 401(k) plans or such other
retirements plans (collectively, "Retirement Plans"). The Transferred Employees
will be eligible to participate in such Health Plans of Buyers without regard to
any waiting period or pre-existing condition exclusion period. Transferred
Employees will receive credit under the Retirement Plans for service
26
<PAGE>
(i.e., time worked) as an employee of either Seller prior to the Closing Date to
the extent permitted by such Retirement Plans. If the Retirement Plans do not
allow for the crediting of such service, then Buyers shall use their best
efforts to amend the Retirement Plans as soon as practicable so as allow the
Transferred Employees to receive credit for such service with Sellers. Buyers
covenant and agree to credit the Transferred Employees with respective accrued
sick leave and vacation benefits set forth on Schedule 8.01 of the Disclosure
Schedule, with respect to service as an employee of Seller prior to the Closing
Date and to allow the Transferred Employees to use such accrued leave and
benefits in accordance with Buyer's existing policies regarding the use of paid
time off.
8.02 Notification Acts. All notices required pursuant to the Federal
Worker Adjustment and Retraining Notification Act of 1988 (the "WARN Act"), with
respect to acts taken by or omissions of Buyers subsequent to the Closing Date,
shall be the responsibility of Buyers, as well as all liability with respect
thereto. Buyers shall indemnify and hold Sellers harmless from and against any
and all loss or liability imposed under the WARN Act resulting from Buyers'
failure to offer employment to, or the subsequent termination of employment of,
the Transferred Employees.
8.03 Expenses. The parties to this Agreement shall bear their
respective expenses incurred in connection with the preparation, negotiation,
execution and performance of this Agreement, including, without limitation, all
fees and expenses of agents, consultants, representatives, counsel and
accountants.
8.04 Further Assurance. Each of the parties shall execute such
documents and other papers and take such further commercially reasonable actions
as may be reasonably required or desirable to carry out the provisions of this
Agreement and the transactions contemplated hereby. With respect to licenses,
Permits and Contracts which cannot be transferred or assigned effectively
27
<PAGE>
without the consent of another Person, and if said consents have not been
obtained prior to Closing, Sellers shall cooperate with Buyers in a commercially
reasonably manner in obtaining such consents promptly. If such consents are not
obtained, Sellers shall use commercially reasonable efforts to assist Buyers in
obtaining the benefits thereof in some other manner.
8.05 Books, Records and Information. Sellers agree that all documents
and other tangible things that are retained by Sellers pursuant to this
Agreement and that are related to the Business, if any, shall be open for
reasonable inspection by representatives of Buyers on reasonable notice during
regular business hours for a period of twelve (12) months following the Closing
and that Buyers may, during such period, at their expense make such copies
thereof as they may reasonably request. Similarly, Buyers agree that Sellers and
their representatives shall have access, on reasonable notice during regular
business hours, for a period of twelve (12) months following the Closing, to any
and all records and documents transferred to Buyers hereunder for either
Sellers' tax purposes and as may be necessary for either Seller to file other
reports or information with any Governmental Body, and that either Seller may,
during such period, at its expense make such copies thereof as it may reasonably
request. Sellers also agree that Buyers shall have reasonable access to all
Retention Samples and Batch Records retained by Sellers for a period of one (1)
year beyond any expiration date pertaining to any applicable Products, but only
to the extent not needed by Sellers.
8.06 Restrictive Use of "M.D. Pharmaceutical Vitamins". Buyers shall
not use the name "M.D. Pharmaceutical Vitamins" or any variation thereof, other
than for the sale of vitamin products to United States military commissary and
exchange outlets ("Military Outlets"). Buyers acknowledge and agree that the
rights being transferred hereunder by Sellers to Buyers with respect to the use
of the name "M.D. Pharmaceutical Vitamins" are limited to the sale of vitamin
products to said Military Outlets and for no other use.
28
<PAGE>
8.07 Use of Seller's Address. JMED shall permit Buyers to use its
mailing address as the same appears on any packaging or labeling or other
similar material of the Branded Vitamin Products to the extent necessary in
connection with the sale of any inventory (but in no event later than the
earlier of (i) December 31, 1998, and (ii) the expiration of the Transition
Services Agreement); provided that Buyers shall not order any new packaging
which bears JMED's address.
8.08 Forwarding of Purchase Orders. In the event that after the
Closing, Buyers receive any purchaser orders or requests concerning any of the
Excluded Products, Buyers shall promptly notify JMED of such purchase orders or
requests. Any and all purchase orders or written materials received at any time
by Buyers with respect to the Excluded Products shall be promptly forwarded to
JMED.
8.09 Manufacturing by JMED Affiliates. For a period of six (6) months
following the Closing Date, JMED will cause its Affiliate, JMI Canton
Pharmaceuticals, Inc. ("JMI Canton"), to continue manufacturing for Buyers,
those Products previously manufactured by JMI Canton for Sellers prior to the
Closing Date, on reasonable terms agreed to by the parties. Notwithstanding the
foregoing, the obligations under this Section 8.09 shall terminate if JMED sells
or discontinues the business of JMI Canton in any manner whatsoever.
9. CONDITIONS TO OBLIGATION TO CLOSE.
9.01 Conditions to Obligation of Buyers. The obligations of Buyers
hereunder are subject to the fulfillment or satisfaction at or prior to the
Closing of each of the following conditions (any one or more of which may be
waived by Buyers, but only in writing):
(a) The representations and warranties of Sellers set forth in Article
5 above shall be true and correct in all material respects at and as of the
Closing Date with the same force and effect as if such representations and
warranties were made at and as of the Closing Date,
29
<PAGE>
provided that the receipt of such evidence and the closing of the transactions
contemplated herein shall not be, nor be deemed to be, a waiver of the
representations and warranties contained in this Agreement;
(b) All of the terms, covenants and conditions of this Agreement to be
complied with or performed by Sellers at or before Closing shall have been
complied with or performed in all material respects;
(c) Other than as disclosed herein or contemplated hereby, there shall
have been no Material Adverse Change since the date of this Agreement: (i) with
respect to the financial condition, assets or liabilities of the Sellers as such
relates to the Business except for a reduction in Net Working Capital due to
increased payables and a reduction in receivables and inventory in the ordinary
course of business consistent with past practice except for the unusually high
Net Working Capital at the end of 1997; and (ii) with respect to the business of
the Sellers as such relates to the Business;
(d) Sellers shall have delivered to Buyers a certificate to the effect
that each of the conditions specified in Sections 9.01(a) - (c) is satisfied in
all material respects; (e) All applicable waiting periods (and any extensions
thereof) under the HSR Act shall have expired or otherwise been terminated;
(f) Buyers shall have received from Greensfelder, Hemker & Gale, P.C.,
counsel of Sellers, an opinion in form and substance as set forth in Exhibit F
attached hereto, addressed to Buyers and dated as of the Closing Date;
(g) No action or proceeding by any Governmental Body or any Person
shall be pending or threatened to enjoin, restrict or prohibit the purchase and
sale of the Acquired Assets contemplated hereby;
30
<PAGE>
(h) All actions to be taken by Sellers in connection with the
consummation of the transactions contemplated hereby, and all certificates,
opinions, instruments and other documents required to effect the transactions
contemplated hereby will be reasonably satisfactory in form and substance to
Buyers;
(i) Buyers shall have received all Permits (other than those that
require an OTC or prescription drug license or registration) reasonably required
to operate the Business and Manufacture the Products in substantially the same
manner as operated by Sellers prior to Closing;
(j) Buyers shall have received the consent of the landlord to the
assignment of the Lease;
(k) BLI shall have obtained, at customary rates, a title insurance
policy from a reputable title insurance company licensed to do business in the
State of Arizona, insuring the fee interest title in the Real Property to be
acquired hereunder by BLI, free and clear of all Liens other than those
disclosed on Schedule 5.04 of the Disclosure Schedule, none of which interferes
with the current use by Sellers of such Real Property or the structures thereon;
and
(l) The Certificate of Occupancy currently in existence with respect to
the JMI-Phoenix Facility will be in existence on the Closing Date.
9.02 Conditions to Obligation of Sellers. The obligations of Sellers
hereunder are subject to the fulfillment or satisfaction at or prior to the
Closing of each of the following conditions (any one or more which may be waived
by Sellers, but only in writing):
(a) The representations and warranties of Buyers set forth in Article 6
above shall be true and correct in all material respects at and as of the
Closing Date with the same force and effect as if such representations and
warranties were made at and as of the Closing Date, provided that the receipt of
such evidence and the closing of the transactions contemplated herein
31
<PAGE>
shall not be, nor be deemed to be, a waiver of the representations and
warranties contained in this Agreement;
(b) All of the terms, covenants and conditions of this Agreement to be
complied with or performed by Buyers at or before Closing shall have been
complied with or performed in all material respects;
(c) Buyers shall have delivered to the Sellers a certificate to the
effect that each of the conditions specified in Sections 9.02(a) - (b) is
satisfied in all material respects;
(d) All applicable waiting periods (and any extensions thereof) under
the HSR Act shall have expired or otherwise been terminated;
(e) Sellers shall have received from Kramer, Levin, Naftalis & Frankel,
counsel for Buyers, an opinion in form and substance as set forth in Exhibit G
attached hereto, addressed to Sellers, and dated as of the Closing Date;
(f) No action or proceeding by any Governmental Body shall be pending
or threatened by any Person to enjoin, restrict or prohibit the purchase and
sale of the Acquired Assets contemplated hereby; and
(g) All actions to be taken by Buyers in connection with consummation
of the transactions contemplated hereby and all certificates, opinions,
instruments and other documents required to effect the transactions contemplated
hereby will be reasonably satisfactory in form and substance to Sellers.
10. INDEMNIFICATION.
10.01 Survival of Representations and Warranties. The representations
and warranties of Sellers contained in this Agreement shall survive the Closing
for the benefit of Buyers as follows: (i) as to the representations and
warranties contained in Section 5.20 of this Agreement,
32
<PAGE>
for five (5) years following the Closing; and (ii) as to all other
representations and warranties, for two (2) years following the Closing. The
representations and warranties of Buyers shall survive the Closing for the
benefit of Sellers until two (2) years following the Closing.
10.02 Indemnification by Sellers. Subject to the applicable limitations
set forth in Section 10.05 hereof, Sellers shall, jointly and severally,
indemnify Buyers and their respective Affiliates, directors, officers,
employees, and their respective heirs, personal representatives, successors and
assigns (collectively, the "Buyer Indemnified Parties") against and hold each of
them harmless from any and all damage, claim, action, suit, proceeding,
judgment, loss, liability, cost and expense (including reasonable attorneys'
fees and expenses) (collectively, "Losses") incurred or suffered by any Buyer
Indemnified Party arising out of or relating to: (i) any breach of any
representation, warranty, covenant or agreement of Sellers contained in this
Agreement or in any Transaction Document; or (ii) the operations of Sellers in
connection with the Business prior to the Closing Date (except for the Assumed
Liabilities which will be the joint and several responsibility of each Buyer);
or (iii) the failure of either Seller to perform any of its respective
obligations or covenants under this Agreement or any Transaction Document; or
(iv) the failure of Sellers to comply with any applicable Law with respect to
this Agreement or any Transaction Document; or (v) any product liability claim
for Product Manufactured by either Seller prior to the Closing Date, regardless
of when any such claim accrues, arises or is asserted, provided, however, that
Sellers shall not be responsible to the extent such claim results from (A) any
negligent acts or omissions of either Buyer, (B) any marketing or promotional
statements, claims or assertions of either Buyer with respect to Products sold
after the Closing Date, or (C) any change, modification or manipulation of the
Products in any way by either Buyer or by any third party; or (vi) the presence,
or alleged presence, of digitalis or any other contaminant in plantain which is
an ingredient in any Product
33
<PAGE>
Manufactured by either Seller prior to the Closing Date; or (vii) any statement
made prior to the Closing Date by or on behalf of either Seller that any
Governmental Body asserts created drug status for any Product that did not
comply with all requirements of Law applicable to drugs, provided, however, that
Sellers shall not be responsible for any statements made in catalogs or other
marketing materials released or distributed after the Closing Date.
Notwithstanding anything herein to the contrary, Sellers shall be responsible
for any Products Manufactured by Sellers prior to Closing to the extent that
said Products were contaminated, misbranded or adulterated prior to Closing.
10.03 Obligation of Buyer to Indemnify. Buyers shall, jointly and
severally, indemnify Sellers and their respective Affiliates, directors,
officers and employees, and their respective heirs, personal representatives,
successors and assigns (collectively, the "Seller Indemnified Parties") against
and hold each of them harmless from any and all Losses incurred or suffered by
any Seller Indemnified Party arising out of or relating to (i) any breach of any
representation, warranty, covenant or agreement of either Buyer contained in
this Agreement or in any Transaction Document; or (ii) claims with respect to
the use of the Acquired Assets by either Buyer or the operations of either Buyer
with respect to the Business subsequent to the Closing Date; or (iii) the
failure of either Buyer to perform any of its respective obligations or
covenants under this Agreement or any Transaction Document, including without
limitation, either Buyer's failure to pay or perform, in a timely manner, the
Assumed Liabilities, or (iv) failure of Buyer to comply with the WARN Act with
respect to the JMI-Facility, if applicable; or (v) product liability claims for
any Product Manufactured by either Buyer after the Closing Date; or (vi) any
statement made after the Closing Date and any statement made in catalogs or
other marketing materials (whether said catalogs and marketing materials are
newly printed or were previously printed by JMED) which are released or
distributed after the Closing Date by or on behalf of either Buyer that any
Governmental
34
<PAGE>
Body asserts creates drug status for any Product that does not comply with all
requirements of Law applicable to drugs.
10.04 Indemnification: Notice and Settlements. A Person seeking
indemnification pursuant to Section 10.02 or 10.03 (an "Indemnified Party") with
respect to a claim, action, suit or proceeding by a Person who is not a Buyer
Indemnified Party or a Seller Indemnified Party shall give prompt written notice
to the party from which such indemnification is sought (the "Indemnifying
Party") of the assertion of any claim, or the commencement of any action, suit
or proceeding, in respect of which indemnity may be sought hereunder, provided
that the failure to give such notice shall not affect the Indemnified Party's
rights to indemnification hereunder unless such failure shall prejudice in any
material respect the Indemnifying Party's ability to defend such claim, action,
suit or proceeding. The Indemnifying Party shall have the right to assume the
defense of any such action, suit or proceeding at its expense. If the
Indemnifying Party shall elect not to assume the defense of any such action,
suit or proceeding or fails to make such an election within thirty (30) days
after it receives such notice pursuant to the first sentence of this Section
10.04, the Indemnified Party may assume such defense with counsel of its choice
and at the expense of the Indemnifying Party and shall defend such claim,
action, suit or proceeding diligently and in good faith. The Indemnified Party
shall have a right to participate in (but not control) the defense of an action,
suit or proceeding defended by the Indemnifying Party hereunder and to retain
its own counsel in connection with such action, suit or proceeding, but the fees
and expenses of such counsel shall be at the Indemnified Party's expense;
provided, however, that the Indemnifying Party shall bear the expenses as
incurred of counsel to the Indemnified Party if (i) the Indemnifying Party and
the Indemnified Party have mutually agreed in writing to the retention of such
counsel and the payment of such counsel's fees and expenses by the Indemnifying
Party, or (ii) the named parties in any such
35
<PAGE>
action, suit or proceeding (including impleaded parties) include the
Indemnifying Party and the Indemnified Party, and representation of the
Indemnifying Party and the Indemnified Party by the same counsel would create a
conflict, provided further that if the Indemnifying Party is obligated to pay
the fees and expenses of such counsel, the Indemnifying Party shall be obligated
to pay only the fees and expenses associated with one attorney or law firm, as
applicable, for the Indemnified Party, as reasonably approved by the
Indemnifying Party. An Indemnifying Party shall not be liable under Section
10.02 or 10.03 for any settlement affected without its written consent, which
consent will not be unreasonably withheld or delayed, of any claim, action, suit
or proceeding in respect of which indemnity may be sought hereunder.
10.05 Limitations on Indemnification. (a) Except as otherwise provided
herein, Buyers shall not be entitled to indemnification by Sellers for Losses
under Section 10.02, unless and until the aggregate amount of such Losses
incurred exceeds Three Hundred Seventy-Five Thousand Dollars ($375,000.00),
whereupon Sellers shall be obligated to indemnify the Buyer Indemnified Party
for the full amount of any such Losses. Notwithstanding the foregoing, Sellers'
obligation to indemnify the Buyer Indemnified Party shall be limited to the
aggregate amount of the Purchase Price (the "Maximum Liability") reduced at the
end of each one year anniversary following the Closing Date, by an amount equal
to twenty percent (20%) of the Maximum Liability. Notwithstanding anything to
the contrary contained in this Section 10.05, none of the limitations contained
in this Section 10.05 shall apply to any Losses under items (vi) and (vii) of
Section 10.02.
(b) The amount of any Losses for which indemnification is provided
under this Article 10 shall be reduced by the amount of any insurance proceeds
received by the Indemnified Party with respect to any Losses.
36
<PAGE>
11. TERMINATION. 11.01 Termination. This Agreement may be terminated and
the transactions contemplated hereby may be abandoned prior to the Closing Date:
(i) by the mutual consent of JMED and Twin Labs; (ii) by JMED if events occur
(other than events caused by either Seller) which render impossible the
satisfaction of one or more of the conditions set forth in Section 9.02; (iii)
by Twin Labs if events occur (other than events caused by either Buyer) which
render impossible the satisfaction of one or more of the conditions set forth in
Section 9.01; or (iv) by JMED or Twin Labs if the Closing has not occurred on or
before April 30, 1998.
11.02 Procedure Upon Termination. In the event of the termination of
this Agreement by either party as provided in Section 11.01 (other than pursuant
to clause (i) of Section 11.01), written notice thereof shall forthwith be given
to the other party to this Agreement, and this Agreement (other than the
provisions of Sections 8.03, 10.02, 10.03 and 12.09) shall terminate without
further action by Sellers or Buyers.
12. MISCELLANEOUS.
12.01 Certain Definitions. As used in this Agreement, the following
terms shall have the meanings set forth below:
(a) "Affiliates" of a Person means any other Person directly or
indirectly, through one or more intermediaries, controlled by, controlling or
under common control with said first Person.
(b) "Business" means and includes the blending, tableting,
encapsulating, manufacturing, packaging, distribution, marketing and sale of the
Branded Vitamin Products and the Contract Manufactured Products by either Seller
and the operation of the JMI-Phoenix Facility and the Leased Property.
37
<PAGE>
(c) "Contract" means any contract, agreement, indenture, note, bond,
loan, instrument, lease, conditional sale contract, mortgage, license,
franchise, commitment or other arrangement or agreements, whether written or
oral.
(d) "Environmental Claim" means any accusation, allegation, notice of
violation, action, claim, Lien, demand, abatement or other Order or direction
(conditional or otherwise) by any Governmental Body or any Person for personal
injury (including sickness, disease or death), property damage, damage to the
environment, nuisance, pollution, contamination or other adverse effects on the
environment, or for fines, penalties or restrictions resulting from or based
upon (i) the existence, or the continuation of the existence, of a Release by
JMI-Phoenix (including, without limitation, sudden or non-sudden accidental or
non-accidental Releases) of any Hazardous Material into or onto the environment
(including, without limitation, the air, soil, surface water or groundwater) at,
in, by, from or related to the JMI-Phoenix Facility or any activity conducted
thereon by JMI-Phoenix, (ii) the environmental aspects of the transportation,
storage, treatment or disposal of Hazardous Materials in connection with the
operation of the JMI-Phoenix Facility by JMI-Phoenix; or (iii) the violation, or
alleged violation, of any Environmental Laws or Orders of or from any
Governmental Body by JMI-Phoenix relating to environmental matters connected
with the JMI-Phoenix Facility.
(e) "Environmental Law" means any Law concerning Releases into any part
of the natural environment, or activities that might result in damage to the
natural environment, or any Law that is concerned in whole or in part with the
natural environment and with protecting or improving the quality of the natural
environment and protecting public and employee health and safety and includes,
but is not limited to, the Comprehensive Environmental Response, Compensation,
and Liability Act ("CERCLA") (42 U.S.C. ss. 9601 et seq.) the Hazardous
Materials
38
<PAGE>
Transportation Act (49 U.S.C. ss.1801 et seq.), the Resource Conservation and
Recovery Act (42 U.S.C. ss. 6901 et seq.), the Clean Water Act (33 U.S.C. ss.
1251 et seq.), the Clean Air Act (33 U.S.C. ss. 7401 et seq.), the Toxic
Substances Control Act (15 U.S.C. ss. 2601 et seq.), the Federal Insecticide,
Fungicide and Rodenticide Act (7 U.S.C. ss. 136 et seq.) and the Occupational
Safety and Health Act (29 U.S.C. ss. 651 et seq.) ("OSHA"), as such laws have
been amended or supplemented, and the regulations promulgated pursuant thereto,
and any and all analogous state or local statutes, and the regulations
promulgated pursuant thereto.
(f) "Environmental Matters" means any matter arising out of or relating
to the production, storage, transportation, disposal or Release of any Hazardous
Material or otherwise arising out of or relating to safety, health or the
environment which could give rise to liability or require the expenditure of
money to address, and shall include, without limitation, the costs of
investigating and remediating any of the foregoing matters, any fines and
penalties arising in connection therewith, and any claim in respect thereof for
damages or injunctive relief for alleged personal injury, property damage or
damage to natural resources under common law or other Environmental Law.
(g) "Environmental Permit" means any Permit, approval, authorization,
license, variance, registration, or permission required under any applicable
Environmental Laws and all supporting documents associated therewith.
(h) "Governmental Body" means any governmental or regulatory body, or
political subdivision thereof, whether federal, state, local or foreign, or any
agency, instrumentality or authority thereof, or any court or arbitrator (public
or private).
(i) "Hazardous Materials" means any substance, material or waste which
is regulated by any local, state or federal Governmental Body in the
jurisdiction in which either of
39
<PAGE>
the Sellers conduct business, or the United States, including, without
limitation, any material or substance which is defined as a "hazardous waste,"
"hazardous material," "hazardous substance," "extremely hazardous waste" or
"restricted hazardous waste," "subject waste," "contaminant," "toxic waste" or
"toxic substance" under any provision of Environmental Law, including but not
limited to, petroleum products, asbestos and polychlorinated biphenyls.
(j) "Knowledge" means, with respect to an individual, the actual
present knowledge of such individual. A Person (other than an individual) will
be deemed to have "Knowledge" of a particular fact or other matter if any
individual who serves as a director, officer, partner, executor or trustee of
such Person (or in any similar capacity) has, or at any time had, Knowledge of
such fact or matter.
(k) "Law" means any federal, state, local or foreign law (including
common law), statute, code, ordinance, rule, regulation or other requirement or
guideline.
(l) "Legal Proceeding" means any judicial, administrative or arbitral
actions, suits, proceedings (public or private), claims or governmental
proceedings or investigations.
(m) "Lien" means any lien, pledge, hypothecation, levy, mortgage, deed
of trust, security interest, claim, lease, option, right of first refusal,
easement, or other real estate declaration, covenant, condition, restriction or
servitude, transfer restriction under any shareholder or similar agreement,
encumbrance or any other restriction or limitation whatsoever.
(n) "Material Adverse Change" means any material adverse change in the
business, properties, results of operations, prospects or condition (financial
or otherwise) of either of the Sellers, in each case that relate to the Business
or the Acquired Assets.
(o) "Order" means any order, injunction, judgment, decree, ruling,
writ, assessment or arbitration award.
40
<PAGE>
(p) "Permits" means any approvals, authorizations, registrations,
consents, licenses, permits or certificates by any Governmental Body.
(q) "Person" means any individual, corporation, partnership, firm,
joint venture, association, joint-stock company, trust, unincorporated
organization, Governmental Body or other entity.
(r) "Products" means the Branded Vitamin Products and the Contract
Manufactured Products.
(s) "Release" means any release, spill, effluent, emission, leading,
pumping, injection, deposit, disposal, discharge, dispersal, leaching, or
migration into the environment, or into or out of any property owned, operated
or leased by JMI-Phoenix, including the movement of any Hazardous Material
through or in the air, soil, surface water, groundwater, or property.
(t) "Remedial Action" means all actions, including, without limitation,
any capital expenditures, required or voluntarily undertaken to (i) clean up,
remove, treat, or in any other way address any Hazardous Material or other
substance in the indoor or outdoor environment; (ii) prevent the Release or
threat of Release, or minimize the further Release of any Hazardous Material so
it does not migrate or endanger or threaten to endanger public health or welfare
of the indoor or outdoor environment; or (iii) perform pre-remedial studies and
investigations or post-remedial monitoring and care.
12.02 Notices. All notices and other communications made pursuant to
this Agreement shall be in writing and shall be deemed to have been given or
delivered upon receipt if given by hand, or three (3) business days after being
mailed by registered or certified mail, postage prepaid, return receipt
requested, in each case addressed as follows:
41
<PAGE>
(i) If to either Seller:
Jones Medical Industries, Inc.
1945 Craig Road
St. Louis, Missouri 63146
Attention: Dennis M. Jones
with a copy to:
Greensfelder, Hemker & Gale, P.C.
10 South Broadway, Suite 2000
St. Louis, Missouri 63102
Attention: Edward A. Chod, Esq.
(ii) If to either Buyer:
Twin Laboratories Inc.
2120 Smithtown Avenue
Ronkokoma, New York 11779
Attention: Philip M. Kazin, Esq.
with a copy to:
Kramer, Levin, Naftalis & Frankel
919 Third Avenue
New York, New York 10022-3903
Attention: Howard A. Sobel, Esq.
Any party may, by notice given in accordance with this Section 12.02 to the
other party, designate another address or Person for receipt of notices
hereunder.
12.03 Construction. The headings of the Sections of this Agreement and
in the Schedules and Exhibits to this Agreement are inserted for convenience of
reference only and shall not be used in interpreting this Agreement. Unless
specifically stated otherwise, references to Sections, paragraphs, Exhibits and
Schedules refer to the Sections, paragraphs, Exhibits and Schedules to this
Agreement. Terms which are defined in this Agreement shall have the same
meanings when used in the Schedules and Exhibits to this Agreement.
42
<PAGE>
12.04 Schedules and Exhibits. The Disclosure Schedule and all of the
Schedules and Exhibits to this Agreement constitute an integral part of this
Agreement and are hereby incorporated in and made a part of this Agreement.
12.05 Entire Agreement. This Agreement and the agreements, documents
and instruments to be delivered under it constitute the entire understanding and
agreement between Buyer and Sellers concerning the subject matter covered hereby
and supersede all prior agreements, understandings and commitments with respect
to such subject matter.
12.06 Binding Effect. This Agreement shall be binding upon and inure to
the benefit of the parties and their respective successors and assigns;
provided, however, that no party shall assign any of its rights or obligations
hereunder without the prior written consent of the others, except that Buyers
may assign their rights (but not their obligations) hereunder to any
wholly-owned subsidiary of Twin Labs by giving notice thereof to JMED.
12.07 Governing Law. This Agreement shall be construed and enforced in
accordance with and governed by the internal substantive laws of the State of
Delaware without regard to conflict of laws principles.
12.08 Waivers and Amendments; Preservation of Remedies. This Agreement
may be amended, superseded or canceled, and the terms hereof may be waived, only
by a written instrument signed by all parties hereto. No delay on the part of
any party in exercising any right, power or privilege hereunder shall operate as
a waiver thereof. Nor shall any waiver on the part of any party of any such
right, power or privilege, nor any single or partial exercise of any such right,
power or privilege, preclude any further exercise thereof or the exercise of any
other such right, power or privilege. The rights and remedies herein provided
are cumulative and are not exclusive of any rights or remedies that any party
may otherwise have at law or in equity.
43
<PAGE>
12.09 Public Announcements. The parties hereto agree that no disclosure
or public announcement with respect to this Agreement, its contents or any of
the transactions contemplated by this Agreement shall be made by any party
hereto without the prior written consent of the other parties hereto, provided,
however, that nothing contained herein shall restrict Sellers or Buyer from
making any public announcement of the transactions contemplated by this
Agreement to the extent that it, in its sole discretion reasonably exercised, is
of a view that such announcement is required or deemed advisable in order to
meet its obligations under the securities laws or stock exchange requirements in
the United States; provided further that prior to making such announcement, the
party making it shall provide particulars thereof in writing to the other
parties.
12.10 Counterparts; Facsimile Delivery. More than one counterpart of
this Agreement may be executed by the parties hereto, each of which shall be
deemed an original, but all of which shall constitute one and the same document.
This Agreement may be delivered by facsimile and when so delivered will be
binding as though a manually signed document has been delivered. The parties
agree to cooperate to provide each other with original signature pages to any
document delivered by facsimile.
12.11 Variations and Pronouns. All pronouns and any variations thereof
refer to the masculine, feminine, neuter, singular or plural, as the context may
require.
12.12 Severability. If any provision of this Agreement is found or
declared to be invalid or unenforceable by any court or other competent
authority having jurisdiction, such finding or declaration shall not invalidate
any other provision hereof, and this Agreement shall thereafter continue in full
force and effect except that such invalid or unenforceable provision, and (if
necessary) other provisions thereof, shall be reformed by a court of competent
jurisdiction so as to effect insofar as is practicable, the intention of the
parties as set forth in this Agreement, provided
44
<PAGE>
that if such court is unable or unwilling to effect such reformation, the
invalid or unenforceable provision shall be deemed deleted to the same extent as
if it had never existed.
12.13 Preparation of Agreement. Buyer and Sellers have participated in
the preparation and drafting of this Agreement and no inference, assumption or
presumption shall be drawn from the fact that a party hereto or an attorney for
such party prepared and/or drafted this Agreement.
[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS]
45
<PAGE>
IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed as of the day and year first above written. ("Buyers") ("Sellers") TWIN
LABORATORIES INC. JONES MEDICAL INDUSTRIES, INC.
By: /s/Ross Blechman By: /s/Michael T. Bramblett
---------------------- --------------------------
Name: Ross Blechman Name: Michael T. Bramblett
-------------------- --------------------------
Title: President Title: Executive Vice President
-------------------- -------------------------
BRONSON LABORATORIES, INC. JMI-PHOENIX LABORATORIES, INC.
By: /s/Ross Blechman By: /s/Dennis M. Jones
---------------------- --------------------------
Name: Ross Blechman Name: Dennis M. Jones
-------------------- --------------------------
Title: President Title: President
-------------------- -------------------------
46
